loader2
Partner With Us NRI

Gland Pharma Ltd share Price Today

Company details

1,803.55
1,835.00
1,040.05
2,194.00
6M Return -6.28%
1Y Return 71.32%
Mkt Cap.(Cr) 30,057.29
Volume 220,838
Div Yield 1.10%
OI
-
OI Chg %
-
Volume 220,838
NSE

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Pharmaceuticals company Gland Pharma announced Q4FY24 & FY24 results:

Q4FY24 Financial Highlights:

  • Consolidated revenue surged 96% YoY to Rs 15,375 million.
  • Consolidated EBITDA soared 113% YoY to Rs 3,587 million.
  • Consolidated EBITDA margin was at 23% versus 21% in Q4FY23.
  • Base business (ex-Cenexi) revenue grew 50% YoY to Rs 11,737 million.
  • Base business (ex-Cenexi) EBITDA jumped 156% YoY to Rs 4,306 million.
  • Base business (ex-Cenexi) EBITDA margin expanded to 37% in Q4FY24 from 21% in Q4FY23.

FY24 Financial Highlights:

  • Consolidated revenue climbed 56% YoY to Rs 56,647 million.
  • Consolidated EBITDA rose 30% YoY to Rs 13,331 million.
  • Consolidated EBITDA margin stood at 24%, a decline of ~400 basis points due to Cenexi integration.
  • Base business (ex-Cenexi) revenue increased 15% YoY to Rs 41,769 million.
  • Base business (ex-Cenexi) EBITDA jumped 38% YoY to Rs 14,142 million.
  • Base business (ex-Cenexi) EBITDA margin stood at 34% against 28% in FY23.
  • The Board recommends a final dividend of Rs 20 per equity share for the fiscal year ending March 31st, 2024, subject to the approval of our shareholders.

Commenting on the results, Srinivas Sadu, MD & CEO of Gland Pharma, said, “We are delighted to close out the last quarter and FY24 with positive results. This year marked a significant rebound for our base business, and we began an exciting new chapter as we completed our first international acquisition, Cenexi, in Europe. Despite the dynamic business landscape, we've shown resilience and delivered a performance that positions us well for continued growth and success. We see continued momentum in this segment and are optimistic about its future opportunities. The strategic rationale behind Cenexi’s acquisition remains intact, and we expect it to deliver significant value as we move forward.”

Result PDF

View Other Company Results

Gland Pharma Ltd shares SWOT Analysis

Strengths (6)

  • Good quarterly growth in the recent results
  • Growth in Net Profit with increasing Profit Margin (QoQ)
  • Company with Low Debt

Weakness (5)

  • Inefficient use of capital to generate profits - RoCE declining in the last 2 years
  • Inefficient use of shareholder funds - ROE declining in the last 2 years
  • Inefficient use of assets to generate profits - ROA declining in the last 2 years

Opportunity (0)

Data not found

Threats (3)

  • Big Deal (Insider and SAST) sells last month greater than 1% of total shares
  • Big Deal (Insider and SAST) sells last week greater than 1% of total shares
  • Increasing Trend in Non-Core Income
Discover More

Resistance and support

R1 1,838.7
R2 1,852.6
R3 1,870.2
Pivot

1,821.13

S1 1,807.3
S2 1,789.7
S3 1,775.8
EMA SMA
1,826.4
1,815.5
1,803.3
1,761.6
1,836.6
1,796.7
1,819.2
1,783.1
Delivery and volume
Discover More
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
UBS PRINCIPAL CAPITAL ASIA LIMITED Bulk Purchase 2024-06-19 1771.05 825000 BSE
FOSUN PHARMA INDUSTRIAL PTE. LTD. Bulk Sell 2024-06-19 1771.81 9900000 BSE
LAKUMI TRUST Bulk Sell 2024-04-09 1739.1 6165486 NSE
Discover More
Name Category Shares
Fosun Pharma Industrial Pte. Ltd PROMOTER 57.86%

FINANCIALS

Sales
Operating Profit
Profit after Tax
DISCOVER MORE
Equity
Reserves and Surplus
Debt
DISCOVER MORE
Sales
Operating Profit
Profit after Tax
DISCOVER MORE
PE
Debt/Equity
P BV
DISCOVER MORE

Gland Pharma Ltd Stocks COMPARISON

Financials( ₹ in Cr) Gland Pharma Ltd Sun Pharmaceuticals Industries Ltd Divis Laboratories Ltd Cipla Ltd Zydus Lifesciences Ltd
Price 1,824.85 1,520.85 4,596.45 1,480.80 1,073.95
% Change 0.41 0.30 1.64 -0.01 1.60
Mcap ₹ Cr 30,057.29 364,902.86 122,021.50 119,554.91 108,064.50
Revenue TTM ₹ Cr 3,624.60 43,885.68 7,767.51 15,790.60 17,237.40
Net Profit TTM ₹ Cr 781.04 8,560.84 1,823.38 2,513.47 1,997.30
PE TTM 38.91 36.50 76.24 28.08 28.04
1 Year Return 71.32 48.84 27.62 46.72 84.38
ROCE 14.04 16.79 19.30 14.76 16.25
ROE 10.33 16.46 14.89 10.66 14.05
DISCOVER MORE
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 7,958.72 Cr FV: 1.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 29,542.69 26,564.54
LAST 3M 107,300.08 -872.81
LAST 6M 187,950.75 839.71
LAST 12M 304,454.24 86,051.23

Gland Pharma Ltd Information

Stock PE (TTM)
38.91
Promoter Holding
57.86%
Book Value
529.5147
ROCE
14.04%
ROE
10.33%
Description

  • Gland Pharma Ltd is in the Pharmaceuticals sector with the Market Capitalization of worth Rs. 67,419.04 crores, it is incorporated in the year 1978. It has reported the consolidated sales of Rs. 1153.90 crores in June 2021. The company is also listed in the Bombay Stock Exchange (BSE) with the code 543245 and listed in the National Stock Exchange (NSE) with the code GLAND.

    Glen Pharma Ltd was incorporated as Private Company in Hyderabad. The company is primarily involved in the production of injectable drugs. Gland Pharmaceuticals has a global presence in around 60 countries and operates on a business-to-business model in countries like India, the USA, Canada, Australia, and some European countries. Gland Pharma has a total of seven manufacturing units located in different parts of the country. Gland Pharmaceuticals has 1415 product registrations in multiple countries of the world, with 368 product registrations in the USA and 54 registrations in India. The company has all its
    facilities approved by USFDA and has a track record of receiving no warnings. The promoters within the company currently hold 58.14% of the stake in the company.

    The Foreign Institutional Investors (FII) and Domestic Institutional Investors (DII) holds 10.44% and 12.11% of the stake. The balance of 19.32% is by others (retail investors).

    In June 2021, quarterly net sales were Rs. 1,153.90 crores, which has increased by approximately 31% from Rs. 884.21 crores for the April-June 2020 quarter. The quarterly net profit in June 2021 was Rs. 350.68 crores, which has seen a rise by nearly 12% from a net profit of Rs. 313.59 crores in June 2020. In June 2021, operating profit was reported at Rs. 1,137.44 crores, which is also increased by 33% as compared to an operating profit of Rs. 853.76 crores for the quarter ending in June 2020. From Rs. 20.24 in June 2020, the EPS of Gland Pharma Ltd has increased to Rs. 21.41 per share in June 2021. GLAND’s stock closed at Rs. 4131 on 16th August’2021 (NSE) and has returned 86.47% in the last six months and 126.06% in the last year.

Read More
Registered Address

Sy No 143-148 150&151 Nr Gandi, X Roads D P Pally Dundigal, Hyderabad, Telangana, 500043

Tel : 91-40-30510999
Email : investors:glandpharma.com
Website : http://www.glandpharma.com
Registrar

Link Intime India Pvt Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 1
Market Lot Equity Shares : 1
BSE Code : 543245
NSE Code : GLAND
Book Closure Date (Month) :
BSE Group : A
ISIN : INE068V01023

FAQ’s on Gland Pharma Ltd Shares

You can buy Gland Pharma Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Gland Pharma Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Jun 28, 2024 03:58 PM the closing price of Gland Pharma Ltd was Rs.1,824.85.

The latest PE ratio of Gland Pharma Ltd as of Jun 28, 2024 03:58 PM is 38.91

The latest PB ratio of Gland Pharma Ltd as of Jun 28, 2024 03:58 PM is 0.29

The 52-week high of Gland Pharma Ltd share price is Rs. 2,194.00 while the 52-week low is Rs. 1,040.05

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Jun 28, 2024 03:58 PM, the market cap of Gland Pharma Ltd stood at Rs. 30,057.29 Cr.

Download App

Download Our App

Play Store App Store
market app